Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725331 | 1.00 | ALDH1A1 (0.75) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL9533498 | 0.81 | ALDH1A1 (0.81) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL10124460 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL725654 | 0.77 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL725653 | 0.77 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL3335215 | 0.76 | ALDH1A1 (0.72) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL3335212 | 0.76 | ALDH1A1 (0.72) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL23169396 | 0.75 | ALDH1A1 (0.70) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL22901815 | 0.75 | ALDH1A1 (0.70) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL376626 | 0.73 | MAPT (1.00) | ALDH1A1KDM4EMAPTHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432321-B1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-8410095-B2 | Thiazolopyrimidinone derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2432321-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-03-01 | — | — | US | disclosed |
| WO-2010135504-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-11-25 | — | — | WO | disclosed |
| EP-2094696-B1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-20100069407-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-18 | — | — | US | disclosed |
| EP-2094696-A1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008061741-A1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| EP-1201661-A1 | HETEROAROMATIC RING COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069407-A1 | CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | ALDH1A1 931/4885KDM4E 4638/4885MAPT 4670/4885 |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CA, PI4KA | ALDH1A1 2476/4885KDM4E 3250/4885MAPT 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.